Cyclosporin treatment improves skin findings in omenn syndrome.

about

Cyclosporin treatment improves skin findings in omenn syndrome.

Item

http://www.wikidata.org/entity/Q41457963

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cyclosporin treatment improves skin findings in omenn syndrome.

@en

type

Item

label

Cyclosporin treatment improves skin findings in omenn syndrome.

@en

prefLabel

Cyclosporin treatment improves skin findings in omenn syndrome.

@en

P1476

Cyclosporin treatment improves skin findings in omenn syndrome.

@en

P2093

Erdener Ozer

http://www.w3.org/2001/XMLSchema#string

Kaan Yildiz

http://www.w3.org/2001/XMLSchema#string

Nevin Uzuner

http://www.w3.org/2001/XMLSchema#string

Ozden Anal

http://www.w3.org/2001/XMLSchema#string

Ozkan Karaman

http://www.w3.org/2001/XMLSchema#string

Sakine Isik

http://www.w3.org/2001/XMLSchema#string

Sule Caglayan Sozmen

http://www.w3.org/2001/XMLSchema#string

Suna Asilsoy

http://www.w3.org/2001/XMLSchema#string

Yasemin Cakır

http://www.w3.org/2001/XMLSchema#string

Zeynep Arikan Ayyildiz

http://www.w3.org/2001/XMLSchema#string

P2860

Partial V(D)J recombination activity leads to Omenn syndrome

Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A

Reviewing Omenn syndrome.

Novel mutatıons and diverse clinical phenotypes in recombinase-activating gene 1 deficiency.

Omenn syndrome: inflammation in leaky severe combined immunodeficiency.

Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience.

Treatment with cyclosporin A in a patient with Omenn's syndrome.

HLA-haploidentical transplantations for primary immunodeficiencies: a single-center experience.

Identification of anti-inflammatory drugs according to their capacity to suppress type-1 and type-2 T cell profiles.

P304

e54-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/PDE.12522

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25727345

http://www.w3.org/2001/XMLSchema#string